Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICASSO
NCT06485154Phase 4Recruiting
- Sponsor
- University of the Witwatersrand
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolutegravir, lamivudine and tenofovir disoproxil fumarate in human immunodeficiency virus infection (HIV), sponsored by University of the Witwatersrand. Primary endpoint: Efficacy of TLD as first-line antiretroviral therapy at 6 months. Started Jun 2024; status: recruiting.
02
Drugs
dolutegravirlamivudinetenofovir disoproxil fumarate
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06485154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06485154.